37 results on '"Underwood, Patrick"'
Search Results
2. Surgical resident experience with common bile duct exploration and assessment of performance and autonomy with formative feedback
3. Simultaneous resection for colorectal cancer with synchronous liver metastases: current state-of-the-art
4. Resource use for cholecystectomy with versus without cholangiography: A multicenter, propensity-matched analysis
5. A protein-based machine learning approach to the identification of inflammatory subtypes in pancreatic ductal adenocarcinoma
6. The interleukin-1 axis and the tumor immune microenvironment in pancreatic ductal adenocarcinoma
7. Comment on: Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials
8. Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Patient-derived Tumors
9. Infiltration of CD3+ and CD8+ lymphocytes in association with inflammation and survival in pancreatic cancer.
10. Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer.
11. Changing Practice Patterns and Improving Survival for Patients with Pancreatic Ductal Adenocarcinoma
12. A simulation curriculum for laparoscopic common bile duct exploration, balloon sphincterotomy, and endobiliary stenting: Associations with resident performance and autonomy in the operating room
13. Data from Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy
14. Supplementary Data S1, S2 from Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors
15. Figure S5 from Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy
16. Supplementary Tables S1 and S2 from MEF2c-Dependent Downregulation of Myocilin Mediates Cancer-Induced Muscle Wasting and Associates with Cachexia in Patients with Cancer
17. Supplementary Data from Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy
18. Supplemental Figures from MEF2c-Dependent Downregulation of Myocilin Mediates Cancer-Induced Muscle Wasting and Associates with Cachexia in Patients with Cancer
19. Supplementary Methods from MEF2c-Dependent Downregulation of Myocilin Mediates Cancer-Induced Muscle Wasting and Associates with Cachexia in Patients with Cancer
20. Data from MEF2c-Dependent Downregulation of Myocilin Mediates Cancer-Induced Muscle Wasting and Associates with Cachexia in Patients with Cancer
21. Data from Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors
22. Transcriptomic analysis of pancreatic adenocarcinoma specimens obtained from Black and White patients
23. Additional file 4 of Surgical resident experience with common bile duct exploration and assessment of performance and autonomy with formative feedback
24. Additional file 6 of Surgical resident experience with common bile duct exploration and assessment of performance and autonomy with formative feedback
25. Additional file 3 of Surgical resident experience with common bile duct exploration and assessment of performance and autonomy with formative feedback
26. Additional file 1 of Surgical resident experience with common bile duct exploration and assessment of performance and autonomy with formative feedback
27. Additional file 2 of Surgical resident experience with common bile duct exploration and assessment of performance and autonomy with formative feedback
28. Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer
29. Kinematics of treadmill stepping in Infants with Down Syndrome: Preliminary Results
30. Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer
31. XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer
32. Osteopenia is associated with wasting in pancreatic adenocarcinoma and predicts survival after surgery
33. Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216
34. Osteopenia is associated with wasting in pancreatic adenocarcinoma and predicts survival after surgery.
35. It's more than just cancer biology: Health disparities in patients with pancreatic neuroendocrine tumors.
36. Resident and Fellow Performance and Supervision in Surgical Oncology Procedures.
37. Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-X L -Specific Degrader DT2216.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.